Sampling Human is an early-stage synthetic biology diagnostics company that engineers genetically modified yeasts as "Living Information Technology" to detect and classify selected living cells within complex samples. Its core product is a proprietary platform and kit-format called Diagnostics On Target (DOT) that harnesses living cells to analyze other cells and translate vast single-cell data into clinical practice. The company positions the technology as a faster, less expensive, and more precise alternative to large instruments such as flow cytometry. Sampling Human says its biological processing can detect extremely small numbers of target cells among millions of other cells, increasing sensitivity and speed. The company plans to use recent funding to further advance R&D, expand hiring, and pursue business development to broaden access for research institutions and clinicians. Sampling Human is based in San Diego.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2022